Galmed Pharmaceuticals
GLMD
30 hedge funds and large institutions have $19.4M invested in Galmed Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
43% more funds holding
Funds holding: 21 → 30 (+9)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.04% less ownership
Funds ownership: 0.16% → 0.13% (-0.04%)
0% less capital invested
Capital invested by funds: $19.5M → $19.4M (-$57.7K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$130K |
| 2 |
Goldman Sachs
New York
|
+$102K |
| 3 |
Morgan Stanley
New York
|
+$89.2K |
| 4 |
Two Sigma Advisers
New York
|
+$67.1K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$65.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.74M |
| 2 |
Renaissance Technologies
New York
|
-$212K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$26.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$22.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAL
26
Capital Analysts LLC
Fort Washington,
Pennsylvania
| $3K | +$3.46K | +5 | New |
|
|
BCM
27
Bourgeon Capital Management
Darien,
Connecticut
| $2K | – | – | – |
|
|
MAM
28
McCarthy Asset Management
Redwood Shores,
California
| $2K | – | – | – |
|
|
SPIA
29
Steward Partners Investment Advisory
New York
| $1.72K | +$2.08K | +3 | New |
|
|
RFA
30
Reilly Financial Advisors
La Mesa,
California
| $1K | – | – | – |
|
|
31
Bank of America
Charlotte,
North Carolina
| – | -$6K | -11 | Closed |
|
GLMD Hedge Fund Activity: Q1 2021 in Review
30 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2021, worth a combined $19.4M — down 0.3% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GLMD positions and 1 closed out — a net gain of 9 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Squarepoint, adding an estimated $130K. The largest seller was Nantahala Capital Management, cutting an estimated $2.74M.
- 30 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $19.4M of Galmed Pharmaceuticals stock for Q1 2021, down 0.3% quarter-over-quarter.
- 10 funds opened new Galmed Pharmaceuticals positions in Q1 2021 and 1 closed out, a net change of +9 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2021 was Squarepoint, an estimated $130K added.
- The largest Galmed Pharmaceuticals seller in Q1 2021 was Nantahala Capital Management, an estimated $2.74M sold.
Based on aggregated 13F filings for Q1 2021.